文献速递认知障碍与痴呆

早期阿尔茨海默病中甘特奈鲁单抗临床试验中的淀粉样蛋白相关影像学异常(ARIA)

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease.
PubMed 文献 · JAMA Neurol · 2025-01-01

基于GRADUATE I/II两项3期随机双盲安慰剂对照研究及其开放标签延伸期(含PostGraduate)的二次数据分析,描述ARIA特征及ARIA-E的危险因素与临床后果。结果显示,除APOE ε4状态外,Aβ神经病理严重程度和共病脑血管病理可能是ARIA-E的重要基线危险因素;在群体水平,ARIA-E未影响长期认知和功能表现。

要点

  • APOE ε4杂合子HR 2.0(95%CI 1.4-2.8),纯合子HR 4.7(95%CI 3.2-6.7),为ARIA-E基线危险因素。
  • 脑脊液Aβ42较低(HR 0.4,95%CI 0.2-0.7)、Fazekas评分较高(HR 1.6,95%CI 1.3-2.0)等也可能为ARIA-E危险因素。
  • 使用甘特奈鲁单抗期间,ARIA-E发生于24.9%(993例中247例),ARIA-含铁血黄素沉积发生于22.9%(993例中227例)。

核心结论

  • 除APOE ε4等位基因数外,Aβ神经病理严重程度和共病脑血管病理可能对处方抗Aβ单克隆抗体的临床医生及制定个体化安全监测计划具有相关性。
  • 推荐在其他抗Aβ单克隆抗体中评估这些危险因素。

研究设计与样本

  • GRADUATE I/II为3期随机、双盲、安慰剂对照、116周平行组研究,及其开放标签延伸期(含PostGraduate),总甘特奈鲁单抗治疗最长210周(平均125周),于2018年至2023年进行。
  • 研究为多中心试验,涵盖30个国家288个中心;GRADUATE I/II分别入组985和980例50至90岁、有早期症状性阿尔茨海默病及Aβ病理的受试者。
  • PostGraduate入组1382例受试者(其中671例既往随机分配至甘特奈鲁单抗);数据分析时间为2022年11月2日至2023年10月10日。
  • GRADUATE I/II受试者按1:1随机分配至甘特奈鲁单抗或安慰剂,采用9个月剂量递增以降低ARIA风险。

主要发现

  • GRADUATE I/II安全性可评估MRI人群共1939例(平均年龄71.7岁;女性1105例[57.0%])。
  • 脑脊液Aβ42较低(HR 0.4;95%CI 0.2-0.7)、Fazekas评分(HR 1.6;95%CI 1.3-2.0)、总浅表铁质沉着计数(HR 1.9;95%CI 1.3-2.6)和总微出血计数(HR 1.3;95%CI 1.0-1.5)可能为ARIA-E的重要基线危险因素。
  • APOE ε4杂合子携带者HR 2.0(95%CI 1.4-2.8),APOE ε4纯合子携带者HR 4.7(95%CI 3.2-6.7)。
  • 在群体水平,ARIA-E未影响长期认知和功能表现:第116周汇总GRADUATE分析中临床痴呆评定量表-盒子总和调整均值相对差异为-9%,首次ARIA-E时删失后亦然。
  • 使用甘特奈鲁单抗期间,ARIA-E发生于24.9%(993例中247例),ARIA-含铁血黄素沉积发生于22.9%(993例中227例);247例ARIA-E中86.2%(213例)首次ARIA-E发生于第64周前。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Data from 2 phase 3 studies of gantenerumab, GRADUATE I/II, and their open-label extensions represent a resource to further characterize amyloid-related imaging abnormalities (ARIA), including long-term sequelae. OBJECTIVES: To describe the characteristics of ARIA and risk factors and clinical consequences of ARIA-edema (ARIA-E). DESIGN, SETTING, AND PARTICIPANTS: Secondary data collection from the GRADUATE I/II phase 3 randomized, double-blind, placebo-controlled, 116-week parallel-group studies and their open-label extensions, including PostGraduate, with up to 210 (mean, 125) weeks of total gantenerumab treatment were conducted between 2018 and 2023. The study included multicenter trials at 288 sites across 30 countries. GRADUATE I/II enrolled 985 and 980 participants, respectively, with early symptomatic Alzheimer disease (AD) and amyloid-beta (Aβ) pathology who were aged 50 to 90 years. PostGraduate enrolled 1382 participants (671 previously randomized to gantenerumab). Data were analyzed from November 2, 2022, to October 10, 2023. INTERVENTIONS: GRADUATE I/II participants were randomized 1:1 to gantenerumab or placebo. Nine-month uptitration was used to mitigate ARIA risk. MAIN OUTCOMES AND MEASURES: Postbaseline safety monitoring, including brain magnetic resonance imaging (MRI) findings, and adverse events and cognitive assessments. RESULTS: The safety-evaluable MRI population of GRADUATE I/II comprised 1939 participants (mean age, 71.7 years; 1105 female [57.0%]). Severity of AD-related Aβ neuropathology (lower cerebrospinal fluid [CSF] Aβ42, hazard ratio [HR] for CSF Aβ42: 0.4; 95% CI, 0.2-0.7) and comorbid cerebrovascular pathology (Fazekas score: HR, 1.6; 95% CI, 1.3-2.0; total superficial siderosis count: HR, 1.9; 95% CI, 1.3-2.6; total microhemorrhage count: HR, 1.3; 95% CI, 1.0-1.5) may be important baseline risk factors for ARIA-E, in addition to apolipoprotein E (APOE) ε4 status (APOE ε4 heterozygous carrier: HR, 2.0; 95% CI, 1.4-2.8 and APOE ε4 homozygous carrier: HR, 4.7; 95% CI, 3.2-6.7). At the group level, ARIA-E did not impact long-term cognitive and functional performance (relative difference in adjusted means for Clinical Dementia Rating-Sum of Boxes was -9% in pooled GRADUATE analysis at week 116 and when censored at first ARIA-E). While taking gantenerumab, ARIA-E and ARIA-hemosiderin occurred in 24.9% (247 of 993) and 22.9% (227 of 993) participants, respectively; first ARIA-E occurred by week 64 in 86.2% (213 of 247) of participants with ARIA-E. Narratives are provided for all serious symptomatic ARIA-E cases. CONCLUSIONS AND RELEVANCE: These results show that in addition to APOE ε4 allele count, severity of Aβ neuropathology and comorbid cerebrovascular pathology may be relevant for clinicians prescribing anti-Aβ monoclonal antibodies for early AD and developing individualized safety monitoring plans. Evaluation of these risk factors in other anti-Aβ monoclonal antibodies is recommended. TRIAL REGISTRATIONS: ClinicalTrials.gov Identifiers: NCT03444870, NCT03443973, NCT04374253.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Salloway S, Wojtowicz J, Voyle N, et al. Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025. PMID: 39556389. doi:10.1001/jamaneurol.2024.3937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。